HMI-103

DB17684InvestigationalGene Therapies

HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

Code names
HMI-103

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of HMI-103, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In